Little research has been done to test the usefulness of T-lymphoma invasion and metastasis 1 (Tiam1) as a prognostic marker for hepatocellular carcinoma (HCC). In this study, we investigated Tiam1 expression and its prognostic value for HCC. HCC surgical tissue samples were taken from 152 HCC patients who had been followed up for 5 years. Overexpression of Tiam1 (Tiam1 2+ to 3+) was shown in 63.8% of the cases. The Tiam1 expression level did not correlate with any clinicopathological parameters. However, survival analysis showed that the Tiam1 overexpression group had a significantly shorter overall survival time than the Tiam1 downexpression group (p=0.008). Multivariate analysis showed that Tiam1 expression was a significant and independent prognostic parameter (p=0.042) for HCC patients. Tiam1 expression may be a novel and independent predictor for the prognosis of HCC patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ijc.23954 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma.
Int J Cancer
March 2025
Department of Oncology Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
The heterogeneity in prognostic survival and treatment response of hepatocellular carcinoma (HCC) limits the accurate assessment of HCC-specific mortality. This study aimed to identify potential HCC subtypes through latent class analysis (LCA) to improve HCC-specific mortality prediction and optimize treatment recommendations. We analyzed data from 7746 HCC patients in the Surveillance, Epidemiology, and End Results (SEER) databases, incorporating demographic and clinicopathological information and applying LCA to identify HCC subtypes.
View Article and Find Full Text PDFEnhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study.
Front Oncol
February 2025
Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Background: Unresectable hepatocellular carcinoma (HCC) presents significant treatment challenges. While locoregional therapies (LT) and tyrosine kinase inhibitors (TKI) offer some benefits, prognosis remains poor. Immune checkpoint inhibitors (ICI) have shown promise in other oncological settings, suggesting potential benefits in HCC treatment regimens.
View Article and Find Full Text PDFSLC7A11, a disulfidptosis-related gene, correlates with multi-omics prognostic analysis in hepatocellular carcinoma.
Eur J Med Res
March 2025
Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Background: This study sought to establish a risk score signature based on disulfidptosis-related genes (DRGs) to predict the prognosis of hepatocellular carcinoma (HCC) patients.
Methods: The expression data of DRGs from the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) was analyzed to develop and validate a DRG prognostic signature (DRGPS). In vitro, experiments were conducted to explore DRG expressions and roles in HCC tissues and cell lines.
CGREF1 facilitates the cell proliferation, migration and invasion of hepatocellular carcinoma cells via regulation of EIF3H/ Wnt/β-Catenin signaling axis.
BMC Cancer
March 2025
Department of Infectious Diseases, Zhuji People's Hospital of Zhejiang Province, No. 9 Jianmin Road, Taozhu Street, Zhuji City, Shaoxing City, Zhejiang Province, 311800, China.
Background: Although Cell growth regulator with EF-hand domain 1 (CGREF1) has been predicted to be upregulated in multiple cancer types, its definitive function role in carcinogenesis, particularly in hepatocellular carcinoma (HCC), remains poorly characterized.
Methods: Comprehensive bioinformatics analysis was initially conducted using the University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) and Gene Expression Profiling Interactive Analysis (GEPIA) databases to investigate CGREF1 mRNA expression patterns in HCC tissues and their clinical correlation with patient survival outcomes. Experimental validation was subsequently performed through real-time quantitative polymerase chain reaction (RT-qPCR), immunohistochemistry (IHC), and Western blot techniques.
BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.
BMC Immunol
March 2025
Department of Gastroenterology, Jiangnan University Medical Center, Wuxi No.2 People's Hospital, Wuxi, Jiangsu Province, China.
Background: Hepatocellular carcinoma (HCC) is the most frequent kind of liver cancer with high morbidity and mortality rates worldwide. Altered expression of BUB1 (budding uninhibited by benzimidazole 1) gene leads to chromosome instability and aneuploidy. This study investigated the expression of BUB1 and its prognostic value as well as its correlation with immune cell infiltration and immune checkpoints in HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!